|
**Overview**: ToRCH Panel IgG IgM**Introduction**: The ToRCH Panel IgG IgM is a diagnostic tool designed for congenital infection screening using serum samples. In India, acute ToRCH infections in pregnancy (Toxoplasma, Rubella, CMV, HSV) cause significant congenital defects/miscarriages, with IgM indicating recent infection and IgG past exposure/immunity. High morbidity from under-testing in rural/low-SES pregnant women with fever/rash or fetal anomalies, limited serology labs, delayed intervention leading to preventable birth defects. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma/Rubella/CMV/HSV IgG and IgM over 1â€"2 days with high accuracy, valuable for acute vs past infection differentiation in high-risk pregnancies. This diagnostic falls under infectious disease screening and targets pregnant women with symptoms or ultrasound anomalies, addressing accurate detection to guide avidity, amniocentesis, or termination counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive ToRCH profiling and reducing congenital infection burden. Its serum-based approach ensures reliable IgG/IgM assessment.**Other Names**: TORCH IgG IgM Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Combined IgG/IgM ToRCH panel standard in antenatal care; in India, routine in high-risk pregnancies.**Purpose**: The test assesses 8 parameters including Toxoplasma IgG/IgM to guide congenital infection screening, detect acute/past exposure, inform intervention.**Test Parameters**: 1. Toxoplasma IgG, 2. Toxoplasma IgM, 3. Rubella IgG, 4. Rubella IgM, 5. CMV IgG, 6. CMV IgM, 7. HSV IgG, 8. HSV IgM.**Pretest Condition**: No fasting required; patients should be pregnant with risk/symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, fever/rash.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including fetal defects, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM + low-avidity IgG indicates recent primary infection (high fetal risk), necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: Avidity, PCR on amniotic fluid for confirmation.**Test Limitations**: IgM false positives possible; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023. |
